| Trial ID: | L5127 |
| Source ID: | NCT00320879
|
| Associated Drug: |
Irbesartan
|
| Title: |
Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes|Microalbuminuria
|
| Interventions: |
DRUG: irbesartan
|
| Outcome Measures: |
Primary: urinary albumin excretion rate | Secondary: ambulatory blood pressure|glomerular filtration rate|serum potassium|serum creatinine|lipids|renin|aldosterone|NT-proBNP|markers of endothelial function|markers of inflammation|genotypes with possible implications for the risk of cardiovascular disease
|
| Sponsor/Collaborators: |
Sponsor: Steno Diabetes Center Copenhagen
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
52
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2003-09
|
| Completion Date: |
2004-11
|
| Results First Posted: |
|
| Last Update Posted: |
2006-05-18
|
| Locations: |
Steno Diabetes Center, Gentofte, Copenhagen, 2820, Denmark
|
| URL: |
https://clinicaltrials.gov/show/NCT00320879
|
